1.Current status of liver diseases in Korea: Hepatitis B.
Hee Bok CHAE ; Jong Hyun KIM ; Ja Kyung KIM ; Hyung Joon YIM
The Korean Journal of Hepatology 2009;15(Suppl 6):S13-S24
Hepatitis B virus (HBV) infection is the one of the most common causes of the liver diseases in Korea. Since the discovery of Australia antigen (hepatitis associated antigen, or HBsAg later), hepatitis associated antigen was tested widely. HBsAg was detected in 6.6~8.6% in 1980's. Later, it decreased to 5.7% in 1990's. Remarkably, seropositivity of the children deceased to 0.2% after the nationwide vaccination program. Although hepatitis B vaccines are highly effective, the failure rate of perinatal prophylaxis in babies born to HBsAg positive mother was reported to be 4.25%. Treatment of chronic hepatitis B was initiated after the introduction of interferon alpha. Lamivudine opened a new era of oral antiviral agent, and it has been widely used in Korea since 1999. Adefovir was proven to have a good efficacy for lamivudine-resistant chronic hepatitis B. Newer potent antiviral agents such as entecavir, clevudine, and telbivudine are available currently. Further studies are warranted for understanding factors influencing natural history, improving treatment outcomes, and overcoming vaccine non-response.
Acute Disease
;
Antiviral Agents/therapeutic use
;
Hepatitis B/diagnosis/drug therapy/*epidemiology/prevention & control
;
Hepatitis B Surface Antigens/analysis
;
Hepatitis B Vaccines/administration & dosage
;
Hepatitis B, Chronic/epidemiology
;
Humans
;
Immunization Programs
;
Korea/epidemiology
;
Seroepidemiologic Studies
2.Hepatitis B and C Virus Infection and Liver Dysfunction in Patients Receiving Chemotherapy.
Chang Il KWON ; Ji Hyun LEE ; Ki Hyun CHOI ; Kwang Hyun KO ; Sung Pyo HONG ; Seong Gyu HWANG ; Pil Won PARK ; Doyeun OH ; Kyu Sung RIM ; Sehyun KIM
The Korean Journal of Gastroenterology 2006;48(6):408-414
BACKGROUND/AIMS: Liver dysfunction and reactivation of hepatitis virus are well-described complications in cancer patients who receive cytotoxic chemotherapy and may result in varying degrees of liver damage. However, there has been just few reports on such complications and on the preemptive use of lamivudine in Korea. The aims of this study were to determine the prevalence of hepatitis B and C virus infection and the incidence of liver dysfunction in patients with malignancies who receive chemotherapy, to determine the reactivation rate of hepatitis B virus (HBV) in those patients, to evaluate the effect of preemptive use of lamivudine in patients with HBV infection. METHODS: Among 1,477 patients who received chemotherapy due to various malignancies from January 2000 to June 2005, 668 patients with incomplete viral studies or hepatitis related malignancy were excluded. A retrospective study was conducted by reviewing the medical records of remaining 809 patients. RESULTS: The overall prevalence rate of hepatitis B or C virus in patients receiving chemotherapy was 6.55% (53/809). The incidences of liver dysfunction was not significantly different between hepatitis virus positive group and negative group. Reactivation rate of hepatiris B or C virus after chemotherapy was 15% (6/40). In all patients who received lamivudine therapy, aspartate aminotransferase and alanine aminotransferase level were normalized and HBV DNA negativity achieved. CONCLUSIONS: The existence of hepatitis virus in patients receiving chemotherapy did not significantly influence the development of severe liver dysfunction, owing probably to the lamivudine therapy. Further prospective studies are required to ascertain the reactivation of hepatitis virus in patients receiving chemotherapy and the need for prophylactic lamivudine therapy in HBV positive patients.
Adult
;
Antineoplastic Agents/*adverse effects
;
Antiviral Agents/*therapeutic use
;
Female
;
Hepatitis B/diagnosis/epidemiology/*prevention & control
;
Hepatitis C/diagnosis/epidemiology/*prevention & control
;
Humans
;
Lamivudine/*therapeutic use
;
Liver Diseases/chemically induced/*diagnosis/epidemiology
;
Male
;
Middle Aged
;
Neoplasms/complications/drug therapy
;
Prevalence